martes, 16 de enero de 2018

Second FDA approval January 12, 2018

U.S. Food and Drug Administration Header

FDA granted approval to afatinib (Gilotrif, Boehringer Ingelheim Pharmaceutical, Inc.) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.   More Information.  January 12, 2018

Other Hematology/Oncology (Cancer) Approvals & Safety Notifications

No hay comentarios:

Publicar un comentario